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AbstrAct:
p53-based cyclotherapy is proving to be a promising approach to palliate undesired 
effects of chemotherapy in patients with tumours carrying p53 mutations. For 
example, pre-treatment of cell cultures with Nutlin-3, a highly-selective inhibitor of 
the p53-mdm2 interaction, has been successfully used as a cytostatic agent to protect 
normal cells, but not p53-defective cells, from subsequent treatment with mitotic 
poisons or S-phase specific drugs. Here we sought to evaluate whether low doses of 
Actinomycin D (LDActD), a clinically-approved drug and potent p53 activator, could 
substitute Nutlin-3 in p53-based cyclotherapy. We found that pre-treatment with 
LDActD before adding the aurora kinase inhibitor VX-680 protects normal fibroblasts 
from polyploidy and nuclear morphology abnormalities induced by VX-680. However, 
and although to a lower extent than normal fibroblasts, tumour cell lines bearing p53 
mutations were also protected by LDActD (but not Nutlin-3) from VX-680-induced 
polyploidy. We also report that a difference between the response of p53 wild-type 
cells and p53-defective cells to the LDActD/VX-680 sequential combination is that only 
the former fail to enter S-phase and therefore accumulate in G1/G0. We propose that 
drugs that incorporate into DNA during S-phase may perform better as second drugs 
than mitotic poisons in cyclotherapy approaches using LDActD as a cytostatic agent.
INtrODUctION
p53, also known as the “guardian of the genome” 
[1], is perhaps the most studied tumour suppressor to 
date. p53 activation occurs in response to a variety of 
stresses, including DNA damage, and can lead to different 
outcomes in cells [2]. One is a protective cytostatic effect 
that prevents damaged cells from multiplying until lesions 
have been sufficiently repaired. Alternatively, and perhaps 
in response to a combination of signals to p53 indicating 
that the damage is irreparable, p53 activity triggers 
programmed cell death. Highlighting its important role 
in cancer, the P53 gene is mutated or deleted in about 
50% of human adult solid tumours [3]. In many of the 
remaining tumours the p53 pathway is inactivated due to 
alterations in factors regulating p53 [4]. For instance, high 
expression of mdm2 [5], which is p53’s primary negative 
regulator (mdm2 binding to p53 inhibits p53’s function 
and enhances p53 degradation by the proteasome), is a 
frequent event in tumours expressing intact p53. Other 
events leading to impaired p53 function in tumours 
include loss of expression of the mdm2 inhibitor p14ARF 
[6] or the expression of viral oncogenes [7]. 
Most classic chemotherapeutic agents preferentially 
target rapidly dividing cells. However, selectivity towards 
cancer cells is limited and therefore toxicity to normal 
tissues remains a major problem in the clinic. In addition, 
most of these agents are highly mutagenic either by 
causing damage to DNA (directly or indirectly) or, as in 
the case of mitotic poisons, by disrupting chromosome 
distribution. These effects contribute to the killing of Oncotarget 2010; 1:  639 - 650 640 www.impactjournals.com/oncotarget
tumour cells, but also have undesired consequences on 
normal tissues that lead to neutropaenia, hair loss, and 
malaise during treatment and also to an increase in the 
risk of second tumours later in life. Cyclotherapy is an 
emerging strategy that aims at reducing the toxicity, 
mutagenicity, and aneuploidy in normal tissues associated 
with classic chemotherapy [8,9]. In this regard, the current 
knowledge on small-molecule agents that preferentially 
induce p53 mediated cell-cycle arrest rather than apoptosis 
could be of great utility. It is generally accepted that a mild 
activation of p53 should prevent the entry of normal cells 
into S-phase and mitosis [8, 9]. Hence, using low doses 
of p53 activators to induce the protective cytostatic effect 
of p53, could protect normal cells with intact p53 from 
the toxicity of S- and M-phase poisons, including many 
of the classic cancer therapeutics. Instead, and if the p53 
activating  agent  is  sufficiently  selective,  tumour  cells 
with defects in the P53 gene would continue progressing 
through the cell cycle and thus remain sensitive to standard 
therapy. Hence, in principle, this approach should be 
particularly beneficial for patients with tumours that carry 
deletions or inactivating mutations in p53 [8]. 
Indeed, the use of a small molecule, Nutlin-3, a highly 
selective inhibitor of the p53-mdm2 interaction [10], 
has led to promising results. In cultured cells, this non-
genotoxic p53 activator can protect wild-type p53 cells, 
including non-tumour cells, from the cell killing effects 
of DNA synthesis and mitotic poisons [11-13]. It is most 
encouraging that protecting normal tissues with Nutlin-3 
from the effects of a mitotic poison has also proven to be 
a successful strategy in a preclinical model [14]. However 
there are two major drawbacks with Nutlin-3; first, its 
use in the clinic still needs to be approved and, second, 
it needs to be administered at high doses in vivo [10,14]  
In the cyclotherapy study presented here, we 
investigate whether low doses of Actinomycin D 
(LDActD), a clinically-approved antineoplastic agent 
[15], could mimic the protective effects of Nutlin-3 
on normal cells in culture. This concept was based 
on evidence that low nanomolar doses of ActD are not 
significantly  genotoxic  [16],  effectively  increase  p53 
levels and transcription function and induce the expression 
of a panel of genes that overlaps with Nutlin-3-induced 
genes [17]. In addition, this highly-potent compound can 
cause p53-dependent reversible cell-cycle arrest in normal 
keratinocytes [17]. 
Despite the similarities between LDActD and 
Nutlin-3 in cells with regards to their effects on the p53 
pathway, their mechanisms of action differ. Whereas 
Nutlin-3 binds directly to mdm2, ActD inhibits RNA 
synthesis by binding to GC-rich regions in DNA and 
is especially effective at disrupting ribosomal RNA 
biosynthesis [18-21]. This causes a nucleolar stress that is 
sensed by p53 [22, 23]. According to the current model, 
nucleolar stress caused by ActD is able to enhance the 
interaction between mdm2 and ribosomal proteins, such 
as L11, resulting in the impairment of mdm2-dependent 
degradation of p53 [24]. These mechanistic considerations 
led us to test whether LDActD could indeed substitute 
Nutlin-3 in a p53-based cyclotherapy approach. 
rEsULts
Differences in the p53 response after treatment 
with Nutlin-3 and Actinomycin D
In spite of their different mechanisms of action, the 
ability of both LDActD and Nutlin-3 [11] to decrease cell 
growth is highly dependent on wild-type p53. This was 
clearly shown in a recent publication [17] and corroborated 
here for LDActD with a colony-growth assay comparing 
HCT116 colon carcinoma cells expressing wild-type p53 
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Figure 1. LDActD’s effects on cell survival are p53-dependent. HCT116 cells with wild-type p53 or knockout for p53 were treated with 
ActD for 72 hours, after which they were fixed and stained with Giemsa.  Oncotarget 2010; 1:  639 - 650 641 www.impactjournals.com/oncotarget
with HCT116 cells lacking p53 (Figure 1). 
According to the existing literature, there are no 
clear differences between the effects of Nutlin-3 and 
LDActD on the p53 pathway. Phosphorylation of p53 
on serine 15 is not substantially increased in response to 
exposure to either, whereas phosphorylation of p53 on 
serine 46 is increased to a similar extent by both agents 
[17]. Phosphorylation of p53 at serine 392 was initially 
observed after LDActD treatment, but not following 
Nutlin-3 treatment [17]. A more detailed analysis showed 
that phosphorylation at this site is also detectable in 
response to Nutlin-3 [25]. However, because of the nature 
of their p53-activation mechanisms, some differences 
in the speed at which p53 is induced by Nutlin-3 and 
ActD could be expected.  As shown in Figure 2, Nutlin-3 
treatment quickly increases p53 levels, its performance 
being much faster than ActD’s in the same experiment. 
According to current understanding, ActD’s effect on 
mdm2 requires that nucleoli are disrupted and that there 
are sufficient molecules of ribosomal proteins to inhibit 
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Figure 3. Protection of normal human dermal fibroblasts from VX-680-induced polyploidy. (A) Pretreatment with low dose ActD 
decreases the proportion of 8N cells caused by VX-680 in NHDF cells. ActD was added 24 hours post-seeding. VX-680 was added 48 hours 
post-seeding. Cells were harvested 96 hours after seeding. (B) NHDFs were treated with 4 nM ActD for 72 hours, fixed and stained with Giemsa 
(top panel). In the bottom panel, ActD was removed from the medium and cells were allowed to proliferate for 6 days before Giemsa staining. 
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Figure 2. Effects of ActD and nutlin-3 on p53 levels. MCF7 cells were treated with 2 nM ActD, 4 nM ActD or 5 µM Nutlin-3 for the 
indicated time points. Whole cell extracts were prepared and p53 was detected by Western Blotting using the DO1 antibody. Actin was detected 
as a loading control.Oncotarget 2010; 1:  639 - 650 642 www.impactjournals.com/oncotarget
mdm2. This is perhaps a much longer process than directly 
inhibiting mdm2 in order to stabilise p53.  Whether this 
difference in the speed at which the p53 protein is increased 
is also partly due to differences in the permeability and/
or stability of the compounds cannot yet be ruled out. 
Alternatively, Nutlin-3 and ActD may increase p53 in 
certain cell subpopulations only, i.e. in cells at particular 
stages of the cell cycle. These considerations may have 
repercussion for the use of ActD in a cyclotherapy setting.   
Actinomycin D protects normal cells from VX-
680-induced aneuploidy 
It has been recently shown that pretreatment with 
Nutin-3 protects normal keratinocytes from polyploidy 
caused by the small molecule aurora kinase inhibitor VX-
680 (or MK-0457) [11]. Building upon the experience with 
the Nutlin-3/VX-680 combination, we carried out similar 
experiments  using  normal  human  dermal  fibroblasts 
(NHDFs) pretreated with LDActD, instead of Nutlin-3, 
and subsequently exposed to VX-680. VX-680 is a potent 
aurora kinase inhibitor tested for the treatment of solid 
tumours and leukemia. Clinical trials were stopped due 
to electrocardiograph QTc interval prolongation in one 
patient. Nevertheless, because cyclotherapy studies 
using Nutlin-3 have been performed in combination 
with VX-680, we proceeded with the LDActD/VX-680 
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Figure 4. Protection of normal human dermal fibroblasts from VX-680-induced nuclear abnormalities. (A and B) NHDF cells were 
treated for 48 hours with VX-680 alone (labelled as no preinc.), or treated for 48 hours with VX-680 after preincubating with the indicated 
amounts of ActD for 24 hours. Thereafter cells were fixed, stained Giemsa (A) and counted (B). Arrows in (A) indicate cells with abnormal 
nuclei. (C and D) NHDF cells treated as in A and B were allowed to recover for 6 days in drug-free medium. The growth of the cultures in drug-
free medium is quantified in panel (C) by counting the total number of cells per field before and after the recovery period. The average number 
of cells per field with aberrant nuclei before and after the recovery period is shown in panel (D). Error bars correspond to standard deviations. Oncotarget 2010; 1:  639 - 650 643 www.impactjournals.com/oncotarget
combination as this facilitates comparisons between 
Nutlin-3 and LDActD as potential cytostatic agents in 
p53-based cyclotherapy.
Activity of aurora kinases peaks during the G2 and M 
phases of the cell cycle and, accordingly, VX-680’s killing 
effect is mainly by induction of endoreduplication in the 
absence of mitosis resulting in polyploidy and, eventually, 
cell death by mitotic catastrophe [26]. Normal dividing 
cells are susceptible to this effect and indeed proliferating 
NHDFs respond to VX-680 growth inhibition (Figure 1 
supplemental data). Within 48 hours of treatment there 
was a significant increase in the number of polyploid 8N 
cells in cultures treated with 100-500 nM VX-680 (Figure 
3A and Figure 2 supplemental data). At the higher doses 
of VX-680, the proportion of 8N cells diminished in 
association with an increase in the number of sub-diploid 
population. In order to ensure on-target effects of the 
compound we chose to work at a concentration of VX-
680 of 100 nM.
At 1.2 and 1.6 nM, ActD had a weak cell-cycle 
inhibitory effect on NHDF cells that became more evident 
with a slightly higher (2 nM) concentration (Figure 3A). 
The number of dead cells with a sub-diploid DNA content 
was only marginally increased by these doses of ActD. 
Interestingly, NHDF cells are able to resume proliferation 
upon removal of ActD (Figure 3B).
Preincubation of the NHDF cells with 1.2, 1.6 and 2 
nM ActD before VX-680 treatment markedly diminished 
the proportion of polyploid 8N cells (and to some extent 
the number of sub-diploid cells) in a dose-dependent 
manner, demonstrating that LDActD’s cytostatic effect 
can protect normal cells from the effects of aurora kinase 
inhibition. A marked difference in the number of cells in 
G1 was also observed between VX-680 treated (8.3% of 
cells in G1) and ActD/VX-680 treated cells (up to 38.2% 
of cells in G1) (Figure 3A). This suggests that at least part 
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Figure 5. Induction of p53 by ActD in normal fibroblasts. (A) NHDF cells were treated with the indicated amounts of ActD for 4 or 12 
hours. p53 and p21 were analysed by Western blotting. α-tubulin was detected as a loading control. (B) Example of nuclear abnormalities in 
NHDF cells expressing a dominant negative form of p53. The percentage of cells with this sort of aberrant nuclei was 2.5 fold higher than in 
the corresponding cells with intact p53. Severely damaged cells, such as the one in the center of this picture, only appeared in the fibroblasts 
with dominant negative p53.Oncotarget 2010; 1:  639 - 650 644 www.impactjournals.com/oncotarget
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of the protection of NHDFs by LDActD from VX-680 is 
due to inhibition of the G1/S transition by LDActD. The 
importance of this point is highlighted in the Discussion 
section.
We  also  quantified  the  number  of  NHDF  cells 
with aberrant nuclear morphologies induced by VX-680 
(Figure 4). In the cultures treated with VX-680 only, 
a large proportion of the cells have abnormal nuclei. 
However, this number was markedly lower in the cultures 
that had been preincubated with LDActD (Figures 4A and 
4B). Moreover, NHDF cells recovered from the ActD/
VX-680 combination and proliferated after removal of the 
compounds (Figure 4C). In these recovery experiments, the 
number of cells with aberrant nuclei in the cultures treated 
with VX-680 alone as well as with the LDActD/VX-680 
combination did rise after the recovery period. However, 
the number of abnormal cells remained comparatively low 
in the cultures recovering from exposure to the LDActD/
VX-680-combination regimen (Figure 4D). 
Finally, Figure 5A shows that in NHDFs, LDActD 
clearly increased the levels of p53. As expected from 
the results in Figure 2, long-term exposure to low doses 
of ActD is required to increase p53 levels.  The levels 
of the p53 downstream transcriptional target p21, a 
well-established cell-cycle arresting protein were also 
increased by LDActD. This suggests that the protective 
effect of LDActD in NHDF cells could be due to the 
activation of p53 by this compound. We also observed that 
cells with abnormal nuclei are more frequent in NHDF 
cells expressing a dominant negative form of p53 than in 
the corresponding control NHDFs (Figure 5B).
response of p53 defective tumour cell lines to the 
ActD/VX-680 combination
The next question in this study was whether 
preincubation with LDActD affected the outcome of 
VX-680 treatment in tumour cells with defects in the 
P53 gene. For this analysis we chose to work with two 
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human breast cancer cell lines carrying p53 mutations 
frequent in cancers. These cell lines, MDAMB231 and 
MDAMB468 express transcriptionally inactive p53 with 
mutations R280K and R273H, respectively. In both cell 
lines, as in normal fibroblasts, VX-680 treatment alone led 
to an increase in 8N-polyploid cells (Figure 6). However, 
and unexpectedly, LDActD pre-treatment at the doses 
required  to  protect  normal  fibroblasts  also  reduced  the 
population of VX-680-induced 8N cells in these two 
tumour cell types. The effect of LDActD in these tumour 
cells differs from the effect in normal fibroblasts in that 
most MDAMB231 and MDAMB468 cells accumulate in a 
tetraploid state, whereas co-treatment of NHDF cells also 
leads to a rise in the proportion of cells with a 2N DNA 
content. In fact, it can be seen that exposure to LDActD on 
its own led to a small accumulation of cells with 4N DNA 
content in both MDAMB231 and MDAMB468 cultures. 
It may be that this small effect of LDActD becomes more 
apparent in cultures treated with a compound that, like 
VX-680, impairs the G2/M transition. A similar response 
to LDActD combined with VX-680 was observed in 
HCT116 p53-null cells (Figure 7), strongly supporting 
that the effect seen in mutant-p53 tumour cell lines is not 
dependent on the presence of mutant p53. Unlike ActD, 
Nutlin-3 had no effect on the cell-cycle progression of p53 
mutant tumour cells either on its own or in combination 
with VX-680 (Figure 8). This is in line with the high 
selectivity of Nutlin-3 as an inhibitor of the p53/mdm2 
interaction.
However, despite the ability of LDActD to weaken 
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Figure 10. Effect of the LDActD/VX-680 combination on p53-wild type tumour cells. HCT116 cells (p53 wild-type) were treated as 
described in Figure 7 and cell cycle distribution analysis was carried out by FACS.Oncotarget 2010; 1:  639 - 650 648 www.impactjournals.com/oncotarget
VX-680-induced polyploidy in cells with defective p53, 
when cells are allowed to recover from treatment upon 
drug removal, the cell density in the LDActD/VX-680-
treated and VX-680-treated cultures is similar after the 
recovery period (Figure 9). 
In conclusion, we observed that, even at low 
doses, ActD has p53-independent effects, including a 
p53-independent G2/M arresting effect that becomes 
accentuated in the presence of an aurora kinase inhibitor. 
Therefore, we cannot exclude that LDActD could protect 
a proportion of tumour cells with defective p53 from the 
toxicity of this mitotic poison. 
DIscUssION
Motivated by the promising results obtained by 
combining Nutlin-3 with mitotic poisons and the similar 
p53-dependent effects of LDActD and Nutlin-3, we have 
sought to investigate the potential of LDActD as the 
cytostatic agent in a p53-based cyclotherapy approach. In 
summary, we found that:
1. Low non-genotoxic doses of ActD have a 
reversible cytostatic effect on normal human dermal 
fibroblasts and protect them from aneuploidy induced by 
VX-680. 
2. However, treatment with LDActD before VX-
680 also prevents the appearance of 8N cells in tumour 
cells expressing mutant p53 or lacking p53, even though 
LDActD pre-treatment does not weaken the growth 
inhibitory effect of VX-680.
3. Unlike p53-mutant cells and HCT116 p53 
knockout cells, NHDFs as well as HCT116 p53 wild-type 
cells (Figure 10), accumulate in G1/G0 in response to 
LDActD on its own or in combination with the subsequent 
VX-680 treatment. This suggests that wild-type p53 is 
responsible for reducing S-phase entry upon LDActD 
treatment.
The evidence presented here supports that 
pretreatment with a low non-genotoxic dose of ActD, a 
clinically-approved drug, could be an adequate approach 
for cyclotherapy studies in animal models, but at the same 
time raises two issues for consideration. 
First, the therapeutic window for ActD is narrow:   
concentrations of ActD above 1 nM are required in order to 
protect normal fibroblasts effectively, but concentrations 
above 10 nM ActD are genotoxic [17]. Additionally, 
concentrations of ActD above 10 nM also affect NHDF 
viability (Figure 3 supplemental data). However, Nutlin-3 
also shows problems in this regard. This compound is not 
very potent in cells (only active in the micromolar range) 
and needs to be administered to animals at very high doses 
[10, 14]. 
Second, we have evidence suggesting that ActD 
could weaken, at least to some extent, the effect of aurora 
kinase inhibitors in tumour cells with mutant p53. Our 
expectation is that ActD could contribute to decrease the 
growth rate of p53-mutant tumours but, at the same time, 
prevent cell killing by mitotic poisons. Indeed, and in 
agreement with this, low doses of the intercalating agent 
Adriamycin have been reported to protect p53-null tumour 
cells from taxol derived mitotic poisons [27].   
Nevertheless, as argued below, we believe that 
pretreatment with LDActD might have a future in p53-
based cyclotherapy. A key difference between the effects 
of LDActD in p53 wild-type cells and p53-defective cells 
is that only the former undergo arrest in the G1/G0 phase 
of the cell cycle and therefore they do not enter S-phase. 
Hence, we envisage that clinically-approved drugs that 
incorporate into DNA during S-phase, such as gemcitabine 
and cytosine arabinoside, may constitute a better choice 
following pretreatment with LDActD than mitotic 
poisons. In support of this future direction, efficacy has 
been demonstrated in vitro using Nutlin-3 pretreatment 
and  S-phase-specific  chemotherapeutics  as  a  second 
treatment [13]. In conclusion, LDActD merits further 
evaluation in the context of p53-based cyclotherapy.
MAtErIALs AND MEtHODs
cells and reagents
NHDF cells were bought from Promocell. NHDF 
cells expressing a dominant negative form of p53 were 
obtained by stable transfection with an expression vector 
for the murine DD-p53 dominant-negative mutant 
and neomycin resistance as described [28]. HCT116 
and HCT116 p53-null cells were a kind gift from Bert 
Vogelstein (Baltimore). H1299 and MCF-7 cells were 
bought from ATCC. MDAMB231 and MDAMB468 cells 
were bought from CRUK. Actinomycin D was purchased 
from Sigma and stock solution was 2 mg/ml in Ethanol. 
VX-680 was a gift from Phil Cohen (Dundee) and stock 
solution was 10 mM in DMSO.
(±)-Nutlin-3, referred to as Nutlin-3 here, was 
purchased from Cayman Chemicals. It must be noted that 
this product comprises two enantiomers, active (-)-Nutlin 
and  inactive  (+)-Nutlin.  Therefore,  5  μM  Nutlin-3 
corresponds to 2.5 μM of the active enantiomer. The stock 
solution was 50 mM in DMSO.
cell cycle analysis
Fluorescence Activated Cell Sorting (FACS) was 
used to analyse the cell-cycle distribution. Cells were 
seeded in 6-well tissue culture coated plates at required 
density on Day 1 and compounds were added 24 hours 
post-seeding at required doses on Days 2 (cytotastic 
agent) and 3 (VX-680). After required treatment times, 
Bromodexoyuridine (BrdU), supplied by Sigma, was 
added  to  cells  for  30  minutes  at  final  concentration Oncotarget 2010; 1:  639 - 650 649 www.impactjournals.com/oncotarget
of 30 µM. Cells were subsequently harvested using 
trypsinisation, spun down and resuspended in 1 ml of 
PBS. Cells were then fixed in 3 ml of ice-cold ethanol and 
stored for at least 1 hour at 4ºC. Cells were pelleted and 
resuspended in 2 ml of warm pepsin at 1 mg/ml (Sigma) 
in 30 mM HCl pH1.5, for 30 minutes at 37ºC with gentle 
shaking. Cells were then pelleted by centrifugation and 
resuspended in 1 ml of 2M HCl for 20 minutes at RT. 
Cells were washed in excess PBS before washing with the 
antibody buffer (0.5% w/v BSA, 0.5% v/v Tween-20 in 
PBS) and then resuspended in 200 μl of mouse primary 
antibody to BrdU (Becton Dickinson) in antibody buffer 
for 1 hour at RT. After washing with PBS, the samples were 
resuspended in 200 µl of secondary anti-mouse IgG FITC 
conjugated antibody (Sigma) and incubated at RT for 30 
minutes in the dark. The cells were then washed with PBS 
and collected by centrifugation and finally resuspended 
in 500 μl of PBS containing 25 μg/ml propidium iodide 
(Invitrogen) to stain DNA. Samples were analysed using a 
Becton Dickinson FACScan operated by the CELLQuest 
software.
Giemsa staining and Image capture
Cells were seeded in 6-well plates at the required 
density on Day 1 and treated as indicated. Cells were 
fixed with methanol for 7 minutes after which methanol 
was removed and plates left to dry. Cells were stained 
with 5% Giemsa for at least 1 hour before being washed 
with distilled water to remove excess stain. Plates were 
left to dry and then the morphology of the cell nuclei was 
assessed using a Zeiss light microscope under the 10X or 
32X objective. 
Analysis of cell extracts by Western blotting
Cells grown in 6-well plates were harvested by first 
washing them twice in 2 ml of ice-cold PBS before being 
lysed using 1 x Novex NuPage LDS sample buffer (LDS), 
supplied by Invitrogen. All samples were then scraped into 
separate 1.5 ml centrifuge tubes.  Cell lysates were heated 
to 90°C for 5 minutes, sonicated twice for 10 seconds, 
and centrifuged at 13200 rpm for 5 minutes. Protein 
concentrations were then normalised after determining the 
protein concentration using the BCA assay kit (Perbio). 
Once levelled, DTT was added to a final concentration of 
0.1 M.
Proteins  were  separated  on  NuPAGE  TM  4-12% 
Bis-Tris gels in NuPAGE TM MOPS SDS running buffer 
(Invitrogen) at 130V for approximately 100 minutes. 
Proteins were transferred to Immobilon-P membranes 
(Millipore) for 90 minutes at 35 V with 1 x NuPAGE TM 
transfer buffer (Invitrogen). Membranes were incubated 
at RT for 45 minutes in blocking solution (PBS/ 0.1 % 
v/v Tween-20/ 5% w/v non-fat dried milk) with gentle 
shaking. Following blocking, membranes were incubated 
with the appropriate primary antibody (diluted in blocking 
solution) for 1 hour at RT or overnight at 4°C. Membranes 
were washed 4 times for 5 minutes at RT in PBS/0.1 % 
Tween-20, before incubating with the appropriate HRP-
conjugated secondary antibody (Dako) diluted in the 
blocking solution for 45 minutes at RT. Membranes were 
washed a further 5 times for 10 minutes each in PBS/0.1 
% v/v Tween-20, and then a further 2 washes for 5 minutes 
in PBS at RT before detection of chemiluminescent 
signals with ECL solutions according to manufacturer’s 
instructions (Amersham Biosciences). 
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